Registering a new drug in South Korea typically takes 12 to 18 months. The process involves submitting clinical, preclinical, and manufacturing data to the Ministry of Food and Drug Safety (MFDS) for review. Expedited pathways may shorten timelines for priority drugs, such... Read More
A New Drug Application (NDA) in South Korea requires documentation including preclinical and clinical trial data, manufacturing process details, safety and efficacy reports, pharmacological studies, and quality control information. Applicants must also provide Good Manufacturing Practice (GMP) certification and comply with Ministry... Read More
The process for registering a new drug in South Korea involves submitting a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS). It includes preclinical and clinical data, manufacturing details, and safety evaluations. The MFDS reviews the application... Read More
The Ministry of Food and Drug Safety (MFDS) guidelines for new drug delivery systems in South Korea require comprehensive data on safety, efficacy, and performance. Applicants must submit preclinical and clinical data demonstrating the system’s therapeutic benefits, stability, and reliability. Compliance with... Read More
The Ministry of Food and Drug Safety (MFDS) ensures drug safety for controlled substances through strict regulations under the Narcotics Control Act. This includes special licensing, monitoring production, distribution, and prescribing practices. Regular inspections, reporting requirements, and safety assessments prevent misuse, abuse,... Read More
The Ministry of Food and Drug Safety (MFDS) in South Korea requires biosimilar registration to follow guidelines that ensure quality, safety, and efficacy. Applicants must submit comparative data on analytical, non-clinical, and clinical aspects against the reference biologic. Additionally, they must meet... Read More
The MFDS assesses clinical data for Class IV medical devices by conducting a thorough evaluation of submitted trial results, including study design, methodologies, and safety and efficacy outcomes. The agency reviews risk-benefit analyses, examines adverse event data, and may require additional studies... Read More
The MFDS evaluates pharmacovigilance data by assessing adverse event reports, periodic safety update reports (PSURs), and risk management plans (RMPs). They analyze the benefit-risk profile, monitor drug safety trends, and may request additional safety studies. This process helps ensure ongoing drug safety... Read More
The MFDS oversees drug recalls to ensure public safety. It assesses the severity of product defects, categorizes recalls into three classes based on risk, and monitors the recall process. The MFDS also ensures proper communication with healthcare providers, patients, and manufacturers, while... Read More
The MFDS regulates drug distribution in South Korea by enforcing Good Distribution Practice (GDP) guidelines. It monitors the entire supply chain, including storage, transportation, and handling of pharmaceuticals. The MFDS conducts inspections, ensures compliance with safety standards, and mandates accurate record-keeping to... Read More